In order to establish partnerships with corporate ventures finding new paths, associates and opportunities to facilitate the scaling of our portfolio companies in the United states, Camilo Anabalón, Portfolio Manager, traveled to the BIO International Convention in Boston on June 5th.

The event, one of the most important biotechnology and pharma conferences in the world, sets the stage for key players such as large corporations, and service providers, to gather together. A one-on-one partnership event, in which attendees can meet individually with potential partners.

“My main purpose was to schedule meetings in advance with industry personalities that could help us open new paths in the demanding U.S. market, and I think we succeeded with flying colors,” said Camilo.

He also added that, during his participation in the conference, he was able to confirm that “The Ganesha Lab has established itself as a Latin American reference in terms of biotechnology, due to the high level of preparation demonstrated by the startups in our portfolio in relation to other players. As for the ecosystem, I noticed there is an intention to diversify in the area of entrepreneurship, meaning that there is more availability to interact with private capital and make bioentrepreneurship a relevant strategy for both state and private organizations,” he added.

“From the point of view of the portfolio itself, and feedback from other companies, it is evident that they have a focus and a strategy consistent with the industry in which they intend to enter and that they are also addressing issues that are relevant to society in general. It is perceived that our companies have a capacity for execution and a very clear market feedback”, said Anabalón.

Following his participation in the convention in Boston, our Portfolio Manager traveled to NYC to meet with investors and other relevant actors for the soft-landing of our startups, such as Stephen Chambers, Managing Partner of IndieBio, and Duncan Turner, Managing Partner of Hax.

As a finishing touch, Camilo visited the facilities of Cure, a closed ecosystem of biotech startups with a staff of doctors focused on discovering cures for human diseases, a meeting that could have positive impact for The Ganesha Lab and its portfolio, as they tend to invest in pre-seed, seed and series A startups, precisely the type of companies that our company works with.

“I am certain that this journey definitely positioned us even more as one of the most relevant players in biotechnology and entrepreneurship in Latin America, with a great capacity to promote the scaling of our companies to the United States and the synergies and partnerships that were generated both with corporate partners and with other players in the ecosystem,” concluded our Portfolio Manager.